From A-list celebrities to the people in our own lives, breast cancer can can truly happen to anyone — and the stats show it.

In an experiment involving 32 breast cancer survivors, a 45-minute session of either resistance training or high-intensity ...

ProteinQure's PQ203, a novel peptide drug conjugate, gains FDA fast track designation for advanced triple-negative breast ...

An anti-nausea drug may reduce recurrence and death in aggressive breast cancer. Scientists are exploring its broader use in ...

In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe ...

This report details how pleomorphic breast carcinoma evaded initial treatment protocols and spread to 70% of the thorax within months.

Significant advances in breast cancer treatments have improved outcomes, offering personalized care through innovative ...

A novel AI tool could help clinicians personalize cancer treatments through characterization of individual tumor ...

An expert discusses the complexities of sequencing antibody-drug conjugates (ADCs) in metastatic triple-negative breast ...

Breast cancer is the most common cancer in women in the U.S., with the exception of skin cancers, according to the American Cancer Society.

TRIPLE-NEGATIVE breast cancer (TNBC) remains one of the most aggressive subtypes of breast cancer, with limited targeted ...

Agenus Inc. ("Agenus" or the "Company") (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports ...